↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Bristol Myers Squibb$BMY · filed: saw revenue fall 0.2% in FY2025 to $48.2BNew shipTrillion Score 505Fall Risk LowNext year $43.5B–$50.6B sealedCheck ▾Close ▴
What Bristol Myers Squibb filed
Saw revenue fall 0.2% in FY2025 to $48.2 billion, equity 20.5% of assets, and dividend per share up 18 years running. Every figure links to the filing it came from on Bristol Myers Squibb’s card. New ship: no warning signs. Trillion Score 505, #89 of 182 in its field; Fall Risk Low (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $43.5B and $50.6B, an 80% range sealed on 26 Sept 2026 · receipt #1b40a0 · graded in public by the revenue in Bristol Myers Squibb’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Bristol Myers' 18-year dividend streak now depends on **$4.2B** in cost cuts offsetting **$16B** patent cliff through 2028.
$16B
in revenue exposure from patent expirations through 2028
$1.5B
in annual cost savings by year-end 2025 through manufacturing…
$2.7B
targeted by 2027
$36B
in net debt from its Celgene acquisition
Bristol Myers Squibb raised its quarterly dividend for the 18th consecutive year, marking the continuation of a shareholder return policy now directly tied to multi-billion-dollar productivity initiatives designed to offset $16B in revenue exposure from patent expirations through 2028.
The company announced the increase without specifying the new payout rate, maintaining a pattern of modest annual raises that have characterized its dividend policy since 2008. Bristol Myers has committed to $1.5B in annual cost savings by year-end 2025 through manufacturing optimization and administrative headcount reduction, with an additional $2.7B targeted by 2027. The timing of the dividend announcement aligns with the company's need to signal cash generation stability as Eliquis, Opdivo, and Revlimid face generic competition over the next 36 months.
The productivity narrative matters because Bristol Myers operates under a different constraint set than peers. The company carries $36B in net debt from its Celgene acquisition, limiting balance sheet flexibility for large M&A while requiring consistent free cash flow to service obligations and maintain investment-grade ratings. Management has repeatedly stated that dividend growth remains a capital allocation priority above buybacks, a departure from the sector's typical cash return mix. The $4.2B in cumulative savings targets through 2027 represent roughly 8% of current operating expenses, a meaningful recapture that flows directly to free cash flow available for distributions.
What separates this streak from typical pharma dividend stories is the execution timeline. Bristol Myers faces $8B in Eliquis revenue risk when generic versions enter in 2028, representing 18% of total sales. The company's ability to maintain dividend growth past 2027 depends on whether its 14-molecule late-stage pipeline can generate $6B to $8B in new revenue by 2029. Current Street estimates model modest growth for mavacamten (hypertrophic cardiomyopathy) and KarXT (schizophrenia), but neither asset carries blockbuster probability above 60% based on Phase III readouts to date.
Allocators should monitor three specific checkpoints: Bristol Myers' Q2 2025 earnings call in late July, where management typically updates full-year free cash flow guidance; FDA action dates for mavacamten's obstructive HCM indication (August 2025) and KarXT's Phase III readout (Q4 2025); and the company's 2026 R&D day, scheduled for February, where pipeline probability-weighted NPV models will reset Street revenue assumptions for 2028-2030. The productivity savings targets are front-loaded, with 65% of the total $4.2B expected to materialize by end of 2025, creating a 12-month window to assess whether margin expansion translates to sustained payout growth.
The 18-year streak continues because the alternative—cutting a dividend while carrying investment-grade debt and a maturing pipeline—creates institutional shareholder risk Bristol Myers cannot afford. The productivity initiatives are not optionality. They are the dividend.
Branded by POPS4 · proof in 60 seconds
For the principal
Track FDA catalysts through Q4 2025; dividend sustainability hinges on pipeline execution, not balance sheet optionality.
For the operator
Model free cash flow sensitivity to Eliquis generic entry timing; $4.2B savings targets are contractual, not aspirational.
For the house
Underweight pharma dividend plays with patent exposure above 15% of sales; Bristol Myers proves the rule.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
